Evaluating anti-tumor activity of the human anti-PD-1 antibody pembrolizumab using humanized mouse models

被引：0
|
作者：
Linn, Douglas E.
Cristescu, Razvan
Ray, Kallol
Zhang, Shuli
Dhandapani, Sripriya
Kaliyaperumal, Sarav
Yearley, Jennifer H.
Long, Brian J.
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-1657
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1657
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Statin drugs have anti-tumor activity and enhance responses to anti-PD-1 therapy in preclinical models of head and neck cancer
    Burnham, Andre J.
    Kansal, Vikash
    Kinney, Brendan L.
    Paulos, Chrystal M.
    Lesinski, Gregory B.
    Saba, Nabil F.
    Schmitt, Nicole C.
    CANCER RESEARCH, 2022, 82 (12)
  • [32] A novel anti-CTLA-4 antibody with potent anti-tumor activity emerged using humanized CTLA-4 mouse model
    Guo, Chaoshe
    Yang, Yi
    Li, Zhihong
    Li, Yanan
    Chen, Yunyun
    CANCER RESEARCH, 2020, 80 (16)
  • [33] Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal
    Ott, P. A.
    Piha-Paul, S. A.
    Munster, P.
    Pishvaian, M. J.
    Van Brummelen, E. M. J.
    Cohen, R. B.
    Gomez-Roca, C.
    Ejadi, S.
    Stein, M.
    Chan, E.
    Simonelli, M.
    Morosky, A.
    Saraf, S.
    Emancipator, K.
    Koshiji, M.
    Bennouna, J.
    ANNALS OF ONCOLOGY, 2017, 28 (05) : 1036 - 1041
  • [34] A NOVEL ANTI-PD-1/IL15 BI-FUNCTIONAL ANTIBODY WITH ROBUST ANTI-TUMOR ACTIVITY IN MULTIPLE SOLID TUMORS
    Lu, Dan
    Chang, Tzu-Pei
    Polonskaya, Zhanna
    Martomo, Stella
    Luna, Xenia
    Zhang, Zhikai
    Ng, Stanley
    Patel, Jeegar
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A832 - A832
  • [35] A novel PIKfyve inhibitor, CB371 enhances the anti-tumor activity of anti-PD-1 antibody by modulating cancer immunity.
    Uno, Yuko
    Matsumoto, Hirokazu
    Endo, Hiroko
    Katoh, Yuki
    Yaguchi, Tomonori
    Kawakami, Yutaka
    Sawa, Masaaki
    CANCER SCIENCE, 2022, 113 : 1626 - 1626
  • [36] Robust anti-tumor effects of combined anti-CD4 depleting antibody and anti-PD-1/PD-L1 immune checkpoint antibody treatment in mice
    Ito, Satoru
    Matsushima, Kouji
    Ueha, Satoshi
    Yokochi, Shoji
    Ishiwata, Yoshiro
    Hachiga, Kosuke
    Ogiwara, Haru
    Chand, Krishant
    Nakajima, Takumi
    CANCER RESEARCH, 2015, 75
  • [37] Pharmacokinetic analysis of anti-PD-1 and PD-L1 antibodies and evaluation of their anti-tumor effects
    Hatakeyama, Hiroto
    Kurino, Taiki
    Matsuda, Reiko
    Suzuki, Hiroyuki
    Terui, Ayu
    Uehara, Tomoya
    Arano, Yasushi
    Hisaka, Akihiro
    CANCER RESEARCH, 2019, 79 (13)
  • [38] Combination of Oral WT1 Cancer Vaccine and Anti-PD-1 Antibody Induced the Synergistic Anti-Tumor Effect in Mouse Prostate Cancer Model
    Kitagawa, Koichi
    Gonoi, Reina
    Saito, Hiroki
    Tatsumi, Maho
    Hashii, Yoshiko
    Katayama, Takane
    Shirakawa, Toshiro
    MOLECULAR THERAPY, 2017, 25 (05) : 156 - 156
  • [39] Blocking TGF8R synergistically enhances anti-tumor effects of anti-PD-1 antibody in a mouse model of incomplete thermal ablation
    Ju, Shuguang
    Duan, Xuhua
    Wang, Yingliang
    Zhang, Mengfan
    Bai, Yaowei
    He, Xuelian
    Wang, Chaoyang
    Liu, Jiacheng
    Yao, Wei
    Zhou, Chen
    Xiong, Bin
    Zheng, Chuansheng
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 138
  • [40] A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity
    Luan, Yan
    Chai, Dafei
    Peng, Jianjian
    Ma, Shuli
    Wang, Min
    Ma, Hui
    Li, Xiang
    Fu, Shilong
    Pan, Xiaolong
    Wang, Xiaoxiao
    Qin, Songbing
    Xu, Ting
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2016, 31 : 248 - 256
12345